Tonix Pharmaceuticals Holding is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.16 – an increase of 15.23% over the previous week. Tonix Pharmaceuticals Holding employs 103 staff and has a trailing 12-month revenue of around $12.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.16 |
|---|---|
| 52-week range | $0.12 - $22.14 |
| 50-day moving average | $0.15 |
| 200-day moving average | $3.74 |
| Wall St. target price | $21.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-139.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.133 from 2024-11-18
| 1 week (2024-11-13) | -5.81% |
|---|---|
| 1 month (2024-10-18) | -26.11% |
| 3 months (2024-08-20) | -65.00% |
| 6 months (2024-05-20) | -30.00% |
| 1 year (2023-11-20) | -72.35% |
|---|---|
| 2 years (2022-11-18) | -99.84% |
| 3 years (2021-11-19) | 3098.24 |
| 5 years (2019-11-20) | 9344 |
| Revenue TTM | $12.5 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -51.72% |
| Return on equity TTM | -163.24% |
| Profit margin | 0% |
| Book value | $57.61 |
| Market Capitalization | $18.4 million |
TTM: trailing 12 months
We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.
Tonix Pharmaceuticals Holding's shares were split on a 1:32 basis on 9 June 2024 . So if you had owned 32 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 3100% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.
Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.118 up to $22.1376. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 2.077. This would suggest that Tonix Pharmaceuticals Holding's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tonix Pharmaceuticals Holding Corp. , a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.